OmniAb, Inc.
John Kim has a diverse work experience in various scientific and engineering roles. John is currently working as a Sr. Research Scientist at OmniAb, Inc. since March 2023. Prior to this, they worked at Berkeley Lights, Inc. where they served as a Sr. Application/Development Engineer from February 2021 to March 2023 and as an Application/Development Engineer from December 2018 to February 2021. John also worked as a Postdoctoral Fellow at UC Berkeley College of Engineering for a brief period in 2018.
Prior to their postdoctoral fellowship, John pursued their PhD studies at the University of California, San Francisco and the University of California, Berkeley from 2013 to 2018. Before their graduate studies, they were actively involved in various roles at Johns Hopkins University, including being a part of the Global Health Glaucoma Diagnostics Team and serving as the Cooling Cure Team Leader.
Additionally, John founded Karcinex, LLC and served as the Founder and President from June 2011 to August 2013. John also gained research experience as a Research Technician at the Johns Hopkins Hospital - James Buchanan Brady Urological Institute from April 2010 to August 2013 and as an Intern at the National Cancer Institute from May 2012 to December 2012.
John Kim attended Dos Pueblos High School from 2005 to 2009, where they received their high school diploma. From 2009 to 2012, they studied Biomedical/Medical Engineering at The Johns Hopkins University and earned a Bachelor of Science (B.S.) degree. Following this, they pursued a Doctor of Philosophy (PhD) degree in Bioengineering and Biomedical Engineering simultaneously at the University of California, Berkeley and the University of California, San Francisco from 2013 to 2018.
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.